A pilot clinical trial comparing an acid-buffering formulation (ACIDFORM gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis

British Journal of Clinical Pharmacology
Jose A SimoesChristine Mauck


To compare the effectiveness of an acid-buffering formulation gel (ACIDFORM) with metronidazole gel in the treatment of symptomatic bacterial vaginosis (BV). After a confirmed diagnosis of BV according to the criteria established by Nugent and Amsel, 30 nonpregnant women were enrolled in a randomized, double-blind clinical study. The women were randomly assigned to receive either 5 g ACIDFORM gel (n = 13) or 10% metronidazole gel (n = 17) intravaginally once daily for five consecutive days. Participants were evaluated in two follow-up visits (7-12 days and 28-35 days after treatment). Therapeutic success was defined as the presence of less than three of Amsel's criteria. If three or more criteria were present at first or second follow-up visit, the woman was excluded from the study and treated orally with metronidazole. Nugent scores were recorded at each visit but these were not used to define cure. At the first follow-up visit, 15 (88%) of the women in the metronidazole group were cured compared with only three (23%) in the ACIDFORM group (P < 0.001). The remaining 12 women (10 of the ACIDFORM group and two of the metronidazole group) were considered as failure and were treated orally with metronidazole. At the second follow-...Continue Reading


Jan 1, 1990·Scandinavian Journal of Infectious Diseases·E Holst, A Brandberg
Jan 1, 1989·Gynecologic and Obstetric Investigation·B FredricssonC E Nord
Jan 1, 1983·British Journal of Hospital Medicine·S G Dawson, J R Harris
Mar 1, 1994·American Journal of Obstetrics and Gynecology·C H LivengoodJ L Thomason
Oct 24, 1998·Infectious Diseases in Obstetrics and Gynecology·J A SimoesAnibal Faundes
May 11, 2000·Infectious Diseases in Obstetrics and Gynecology·S Faro
May 19, 2000·Sexually Transmitted Infections·G SchmidE Koumans
Jul 26, 2000·Obstetrics and Gynecology·J PaavonenC P Wajszczuk
Feb 15, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·J van De WijgertK Nelson
May 23, 2001·Infectious Diseases in Obstetrics and Gynecology·J A SimoesS Faro
Mar 28, 2002·Infectious Diseases in Obstetrics and Gynecology·A AroutchevaS Faro


Oct 7, 2011·International Journal of Women's Health·Jean-Pierre Menard
Sep 24, 2014·Pharmaceutics·Ana Raquel CunhaRita Palmeira-de-Oliveira
Oct 18, 2011·Drug Development and Industrial Pharmacy·Raphaela Regina de Araújo Pereira, Marcos Luciano Bruschi
Feb 3, 2016·Frontiers in Microbiology·Daniela MachadoNuno Cerca
Jul 7, 2015·Advanced Drug Delivery Reviews·Rita Palmeira-de-OliveiraJosé Martinez-de-Oliveira
Nov 14, 2006·Biologicals : Journal of the International Association of Biological Standardization·Ian McGowan
Feb 26, 2014·Contraception·Lisa L Bayer, Jeffrey T Jensen
Jan 19, 2011·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·S R R F LeiteR A A Ximenes
Jul 29, 2011·International Journal of STD & AIDS·J SherrardEuropean IUSTI
Aug 24, 2018·Expert Opinion on Drug Safety·Anita L Nelson
Nov 4, 2009·Expert Review of Anti-infective Therapy·Hans Verstraelen, Rita Verhelst
Sep 3, 2013·Journal of Lower Genital Tract Disease·Tina J AguinJack D Sobel

Related Concepts

Instillation, Vaginal
Drug Administration Schedule
Bayer 5360
Vaginal Creams, Foams, and Jellies
Bacterial Vaginosis

Related Feeds

Bacterial Vaginosis

Bacterial vaginosis can increase the risk of sexually transmitted infections and in rare cases lead to pelvic inflammatory diseases. Discover the latest research on Bacterial Vaginosis here.